Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrobell vs Prograf PK Study
NCT02336854Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2015
- Primary completion
- Feb 2015
- Modality
- RNA-Targeting Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tacrolimus in organ transplant rejection and rheumatoid arthritis (RA) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Jan 2015; status: completed.
02
Drugs
tacrolimus
03
Conditions
organ transplant rejectionrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02336854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336854.